DDIT4 and diabetic macular edema: Indeed, administration of an intravitreally administered siRNA targeting the REDD1 mRNA (PF-04523655) in patients with diabetic macular edema showed a trend toward improvement in BCVA when compared to focal/grid laser (+5.8 letters with 3 mg PF-04523655 versus +2.4 letters with laser, p = 0.08) (18).